Fra raske frivillige og HIV - 1- positive forsøgspersoner, som fik tipranavir uden ritonavir, var mean- tallet for ubundet tipranavir i plasma det samme i begge populationer (raske frivillige 0, 015% ± 0, 006%; HIV- positive forsøgspersoner 0, 019% + / - +0, 076%).
From clinical samples of healthy volunteers and HIV-1 positive subjects who received tipranavir without ritonavir the mean fraction of tipranavir unbound in plasma was similar in both populations (healthy volunteers 0.015% ± 0.006%; HIV-positive subjects 0.019% ± 0.076%).